Description

Lenvima (Lenvatinib)

Lenvima® (lenvatinib) is an oral prescription medication used in the treatment of certain types of cancer. It belongs to a class of medicines known as tyrosine kinase inhibitors (TKIs), which work by blocking specific proteins involved in tumor growth and the formation of new blood vessels that supply cancer cells.

Indications

Lenvima is approved for the treatment of several cancers, including:

• Differentiated thyroid cancer that has progressed despite radioactive iodine treatment.
• Advanced renal cell carcinoma (kidney cancer), often in combination with other therapies.
• Unresectable hepatocellular carcinoma (liver cancer).
• Certain types of advanced endometrial cancer when used in combination with immunotherapy.

Treatment eligibility depends on the patient’s medical condition, cancer type, stage of disease, and physician assessment.

How Lenvima Works

Lenvima targets multiple receptor tyrosine kinases involved in tumor angiogenesis and cancer progression. By inhibiting these pathways, it may help slow tumor growth and limit the blood supply that tumors need to grow and spread.

Administration

Lenvima is taken orally once daily, with or without food. The dosage varies depending on the cancer type, patient weight, liver and kidney function, and other individual factors. Patients should follow their healthcare provider’s instructions carefully.

Possible Side Effects

Common side effects may include:

• High blood pressure
• Fatigue
• Diarrhea
• Decreased appetite
• Weight loss
• Nausea
• Muscle and joint pain
• Hand-foot syndrome
• Protein in the urine

Serious side effects can occur and require immediate medical attention. Patients should discuss all potential risks and benefits with their healthcare provider.

Important Safety Information

Regular monitoring may be required during treatment, including blood pressure checks, laboratory tests, and assessment of kidney and liver function. Patients should inform their healthcare team about all medications they are taking and any pre-existing medical conditions.

Conclusion

Lenvima has become an important treatment option for several advanced cancers. By targeting pathways that support tumor growth and blood vessel formation, it can help manage disease progression and improve treatment outcomes for eligible patients. Treatment decisions should always be made in consultation with a qualified healthcare professional.